Abstract:Orphanin FQ (nociceptin, OFQ), a hepatdecapeptide peptide, has been designated as an endogenous ligand at the orphan receptor ORL1, which lacks affinity for opioid receptor ligands. OFQ-like immunoreactivity has been localized in spinal cord areas that are involved in the processing of nociceptive signals. In this study, the effects of spinally administered OFQ on thermal and mechanical nociceptive stimuli were investigated following intrathecal (i.t.) injection in unanesthetized rats bearing chronic indwelling catheters in the subarachnoid space. Intrathecal OFQ produced two distinct acute actions: an opioid-like antinociceptive effect, and antagonism of morphine-induced antinociception. Chronic administration produces tolerance. Acute actions were as follows. First, injection of OFQ alone in the dose range 10-100 nmol produced sustained antinociceptive effects in the tail-flick (baseline latency 1.5-2 s) and paw-pressure tests. These effects peaked at 45-60 min post-injection, were fully reversible, and were observed in absence of discernable motor impairments. Intrathecal naloxone (5 nmol) significantly attenuated the antinociceptive effects of OFQ (50 nmol i.t.) in tail-flick and paw-pressure tests. A 24-h pretreatment with the irreversible opioid receptor antagonist, beta-flunatrexamine (2 nmol i.t.), also attenuated the antinociceptive effects of OFQ (50, 100 nmol i.t.) and of morphine (7.5 nmol i.t.) in both tests. Low doses (1, 5 nmol) of OFQ, which failed to produce antinociception in the tail-flick test involving a baseline latency of 1.5-2 s, produced a strong antinociceptive response when the baseline latency was increased to 5-6 s. Second, intrathecal OFQ, at doses (0.5, 1.0, and 5.0 nmol) that had no antinociceptive activity in the tail-flick (baseline latency 1.5-2 s) and paw-pressure tests, attenuated the antinociceptive effect of morphine (7.5 nmol i.t.) in these tests. However, a threshold OFQ dose (10 nmol) significantly extended the duration of antinociception induced by morphine (7.5 nmol i.t.) or deltorphin (20 nmol i.t.). Chronic actions were as follows. In rats that were rendered tolerant to spinal morphine, by a continuous intrathecal infusion (7.5 nmol/h) of the agonist for 5 days, the OFQ dose-response curves for its antinociceptive effect in the tail-flick and paw-pressure tests were significantly shifted to the right. In separate experiments, repeated intrathecal injection of OFQ (50 nmol) or morphine (7.5 nmol) produced a significant decline in their antinociceptive effects. Thus, intrathecally administered OFQ produces both development of tolerance to its antinociceptive actions and cross-tolerance to the action of morphine.

Accelerated Release and Production of Orphanin FQ in Brain of Chronic Morphine Tolerant Rats1published on the World Wide Web on 18 March 1999.1

[Antagonistic Effect of Orphanin FQ on Morphine Analgesia in Rat Brain].

Bidirectional Modulatory Effect of Orphanin Fq on Morphine-Induced Analgesia: Antagonism in Brain and Potentiation in Spinal Cord of the Rat

Antinociceptive and morphine modulatory actions of spinal orphanin FQ

Endogenous Orphanin FQ: Evidence for a Role in the Modulation of Electroacupuncture Analgesia and the Development of Tolerance to Analgesia Produced by Morphine and Electroacupuncture.

Antagonistic Effect of Orphanin FQ on Opioid Analgesia in Rat

Orphanin Fq Potentiates Formalin-Induced Pain Behavior and Antagonizes Morphine Analgesia in Rats

Nocistatin, a Peptide Reversing Acute and Chronic Morphine Tolerance

Effects of Orphanin FQ on Endomorphin-1 Induced Analgesia

Orphanin FQ Antagonizes the Analgesic Effect of 5-HT in Rat Brain

Orphanin FQ antagonizes the inhibition of Ca(2+) currents induced by mu-opioid receptors.

OFQ and CCK-8 act synergistically in antagonizing morphine analgesia in rats

Orphanin FQ Antagonizes the Inhibition of Ca 2+ Currents Induced by Μ-Opioid Receptors

Nocistatin Reverses the Effect of Orphanin Fq/Nociceptin in Antagonizing Morphine Analgesia

Amelioration effect of Orphanin FQ on immunosuppression from surgically traumatized rats

Ofq Reverses the Kappa-Opioid Receptor-Mediated Depression of Calcium Current in Rat Dorsal Root Ganglion Neurons

Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats

Effect of intracerebroventricular or intrathecal injection of orphanin FQ on pain and acupuncture analgesia in rats

Effect of Intrathecal or Intracerebroventricular Administrition of OFQ on Pain Threshold and Acpuncture Analgesia in Rats

In Vitro and in Vivo Functional Profile Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) As a Low Efficacy Mu Opioid Receptor Modulator.

Accelerated Expression Of Cholecystokinin Gene In The Brain Of Rats Rendered Tolerant To Morphine